Email Page Print Page

BioDelivery Sciences International

Corporate Headquarters

4131 ParkLake Avenue, Suite 225
Raleigh, NC 27612
Tel: 919 582 9050
Fax: 919 582 9051

Toll Free:  1-877-579-4578



Business Development


BDSI has numerous established partnerships worldwide and continues to look for other companies interested in novel products or drug delivery technologies.  We are currently looking for companies interested in the following:


  • Partner for commercialization of BELBUCA outside the U.S.
  • Partner for commercialization of Clonidine Topical Gel, both within and outside the U.S.


BDSI is also interested in opportunities to in-license late-stage or marketed products in the U.S. in the areas of CNS - particularly pain and addiction.


Business Development Contact

Al Medwar

4131 ParkLake Avenue, Suite 225
Raleigh, NC 27612
Tel: 919 582 9050
Fax: 919 582 9051

To contact us, use the form below.

First Name:
Last Name:
Contact Number:
Enter Text Above:

Can't Read It?
Click Below

Get the latest details on our products and services.

Top News

BioDelivery Sciences Announces Preferred Formulary Status for BUNAVAIL on Texas Medicaid
BUNAVAIL moved from non-formulary to preferred status

BioDelivery Sciences Announces Additions to its Board of Directors
Timothy C. Tyson joins BDSI's board as an independent member with over 30 years of pharmaceutical experience

BioDelivery Sciences Cites Impressive Number of Physicians Granted Waiver to Increase Patient Limit for Opioid Dependence Treatment Following Recent HHS Rule
SAMHSA Reports 1,665 Clinicians Granted Waivers at the Increased Limit as of This Week

BioDelivery Sciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference

BioDelivery Sciences Announces Three New Managed Care Agreements; Further Enhancing Access to BUNAVAIL
New contracts improve BUNAVAIL formulary status and give BUNAVAIL access to approximately 200,000 additional prescriptions for buprenorphine products for opioid dependence annually